Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Mesothelioma HELP
Based on 4,060 articles since 2006
||||

These are the 4060 published articles about Mesothelioma that originated from Worldwide during 2006-2015.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. 2015

Hjerpe, Anders / Ascoli, Valeria / Bedrossian, Carlos W M / Boon, Mathilde E / Creaney, Jenette / Davidson, Ben / Dejmek, Annika / Dobra, Katalin / Fassina, Ambrogio / Field, Andrew / Firat, Pinar / Kamei, Toshiaki / Kobayashi, Tadao / Michael, Claire W / Önder, Sevgen / Segal, Amanda / Vielh, Philippe / Anonymous490897 / Anonymous500897 / Anonymous510897. ·Division of Clinical Pathology/Cytology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Huddinge, Sweden. · ·Acta Cytol · Pubmed #25824655.

ABSTRACT: OBJECTIVE: To provide practical guidelines for the cytopathologic diagnosis of malignant mesothelioma. DATA SOURCES: Cytopathologists with an interest in the field involved in the International Mesothelioma Interest Group (IMIG) and the International Academy of Cytology (IAC) contributed to this update. Reference material includes peer-reviewed publications and textbooks. RATIONALE: This article is the result of discussions during and after the IMIG 2012 conference in Boston, followed by thorough discussions during the 2013 IAC meeting in Paris. Additional contributions have been obtained from cytopathologists and scientists who could not attend these meetings, with final discussions and input during the IMIG 2014 conference in Cape Town.

2 Guideline Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendations. 2015

Wolff, Henrik / Vehmas, Tapio / Oksa, Panu / Rantanen, Jorma / Vainio, Harri. ·Finnish Institute of Occupational Health (FIOH) Topeliuksenkatu 41aA 00250 Helsinki Finland. Henrik.Wolff@ttl.fi. · ·Scand J Work Environ Health · Pubmed #25299403.

ABSTRACT: -- No abstract --

3 Guideline Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. 2013

Husain, Aliya N / Colby, Thomas / Ordonez, Nelson / Krausz, Thomas / Attanoos, Richard / Beasley, Mary Beth / Borczuk, Alain C / Butnor, Kelly / Cagle, Philip T / Chirieac, Lucian R / Churg, Andrew / Dacic, Sanja / Fraire, Armando / Galateau-Salle, Francoise / Gibbs, Allen / Gown, Allen / Hammar, Samuel / Litzky, Leslie / Marchevsky, Alberto M / Nicholson, Andrew G / Roggli, Victor / Travis, William D / Wick, Mark / Anonymous2220747. ·Department of Pathology, University of Chicago, Chicago, IL 60637, USA. aliya.husain@uchospitals.edu · ·Arch Pathol Lab Med · Pubmed #22929121.

ABSTRACT: CONTEXT: Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. OBJECTIVE: To provide updated practical guidelines for the pathologic diagnosis of MM. DATA SOURCES: Pathologists involved in the International Mesothelioma Interest Group and others with an interest in the field contributed to this update. Reference material includes peer-reviewed publications and textbooks. CONCLUSIONS: There was consensus opinion regarding (1) distinction of benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiation of epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas, and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Immunohistochemical panels should contain both positive and negative markers. It is recommended that immunohistochemical markers have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (>10% is suggested for cytoplasmic membranous markers). These guidelines are meant to be a practical reference for the pathologist.

4 Guideline Malignant pleural mesothelioma. 2012

Ettinger, David S / Akerley, Wallace / Borghaei, Hossein / Chang, Andrew / Cheney, Richard T / Chirieac, Lucian R / D'Amico, Thomas A / Demmy, Todd L / Ganti, Apar Kishor P / Govindan, Ramaswamy / Grannis, Frederic W / Horn, Leora / Jahan, Thierry M / Jahanzeb, Mohammad / Kessinger, Anne / Komaki, Ritsuko / Kong, Feng-Ming Spring / Kris, Mark G / Krug, Lee M / Lennes, Inga T / Loo, Billy W / Martins, Renato / O'Malley, Janis / Osarogiagbon, Raymond U / Otterson, Gregory A / Patel, Jyoti D / Schenck, Mary Pinder / Pisters, Katherine M / Reckamp, Karen / Riely, Gregory J / Rohren, Eric / Swanson, Scott J / Wood, Douglas E / Yang, Stephen C / Anonymous10708. ·The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Baltimore, MD, USA. · ·J Natl Compr Canc Netw · Pubmed #22223867.

ABSTRACT: -- No abstract --

5 Guideline [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma]. 2010

Scherpereel, A / Astoul, P / Baas, P / Berghmans, T / Clayson, H / de Vuyst, P / Dienemann, H / Galateau-Salle, F / Hennequin, C / Hillerdal, G / Le Pe'choux, C / Mutti, L / Pairon, J-C / Stahel, R / van Houtte, P / van Meerbeeck, J / Waller, D / Weder, W / Anonymous5750671 / Anonymous5760671. ·Dept of Pulmonary and Thoracic Oncology,Hospital Calmette CHRU of Lille 59037 Lille Cedex, France. a-scherpereel@chru-lille.fr · ·Zhongguo Fei Ai Za Zhi · Pubmed #20976998.

ABSTRACT: -- No abstract --

6 Guideline Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010

Stahel, R A / Weder, W / Lievens, Y / Felip, E / Anonymous3940662. ·Clinic and Policlinic of Oncology, University Hospital of Zürich, Switzerland. · ·Ann Oncol · Pubmed #20555061.

ABSTRACT: -- No abstract --

7 Guideline Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. 2010

Scherpereel, A / Astoul, P / Baas, P / Berghmans, T / Clayson, H / de Vuyst, P / Dienemann, H / Galateau-Salle, F / Hennequin, C / Hillerdal, G / Le Péchoux, C / Mutti, L / Pairon, J-C / Stahel, R / van Houtte, P / van Meerbeeck, J / Waller, D / Weder, W / Anonymous770655. ·Dept of Pulmonary and Thoracic Oncology, Hôpital Calmette, CHRU of Lille, 59037 Lille Cedex, France. a-scherpereel@chru-lille.fr · ·Eur Respir J · Pubmed #19717482.

ABSTRACT: Malignant pleural mesothelioma (MPM) is a rare tumour but with increasing incidence and a poor prognosis. In 2008, the European Respiratory Society/European Society of Thoracic Surgeons Task Force brought together experts to propose practical and up-to-dated guidelines on the management of MPM. To obtain an earlier and reliable diagnosis of MPM, the experts recommend performing thoracoscopy, except in cases of pre-operative contraindication or pleural symphysis. The standard staining procedures are insufficient in approximately 10% of cases. Therefore, we propose using specific immunohistochemistry markers on pleural biopsies. In the absence of a uniform, robust and validated staging system, we advice use of the most recent TNM based classification, and propose a three step pre-treatment assessment. Patient's performance status and histological subtype are currently the only prognostic factors of clinical importance in the management of MPM. Other potential parameters should be recorded at baseline and reported in clinical trials. MPM exhibits a high resistance to chemotherapy and only a few patients are candidates for radical surgery. New therapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach should be included in a prospective trial at a specialised centre.

8 Guideline Lung Cancer OncoGuia: surgical pathology report guidelines. 2009

Ramírez, Josep / Montero, M Angeles / Alejo, María / Lloreta, Josep / Anonymous4150648. ·Pathology Department, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. · ·Clin Transl Oncol · Pubmed #20045788.

ABSTRACT: -- No abstract --

9 Guideline Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. 2009

Husain, Aliya N / Colby, Thomas V / Ordóñez, Nelson G / Krausz, Thomas / Borczuk, Alain / Cagle, Philip T / Chirieac, Lucian R / Churg, Andrew / Galateau-Salle, Francoise / Gibbs, Allen R / Gown, Allen M / Hammar, Samuel P / Litzky, Leslie A / Roggli, Victor L / Travis, William D / Wick, Mark R. ·Department of Pathology, University of Chicago, Chicago, IL 60631, USA. ahusain@bsd.uchicago.edu · ·Arch Pathol Lab Med · Pubmed #19653732.

ABSTRACT: CONTEXT: Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. OBJECTIVE: To develop practical guidelines for the pathologic diagnosis of MM. DATA SOURCES: A pathology panel was convened at the International Mesothelioma Interest Group biennial meeting (October 2006). Pathologists with an interest in the field also contributed after the meeting. CONCLUSIONS: There was consensus opinion regarding (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the differential diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Immunohistochemical panels should contain both positive and negative markers. The International Mesothelioma Interest Group recommends that markers have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (>10% is suggested for cytoplasmic membranous markers). These guidelines are meant to be a practical reference for the pathologist.

10 Guideline Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2008

Stahel, R A / Weder, W / Felip, E / Anonymous3200608. ·Clinic and Policlinic of Oncology, University Hospital of Zürich, Switzerland. · ·Ann Oncol · Pubmed #18456764.

ABSTRACT: -- No abstract --

11 Guideline Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: pulmonary adenocarcinoma versus mesothelioma. 2007

Marchevsky, Alberto M / Wick, Mark R. ·Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. marchevsky@cshs.org · ·Appl Immunohistochem Mol Morphol · Pubmed #17525624.

ABSTRACT: There are no firmly established guidelines for the use of antibodies in immunohistology as individual tests or panels. Practicing pathologists must rely on information available in individual publications, review articles, books, and internet-based databases to develop diagnostic immunohistochemical algorithms for their individual practices. In contrast, other medical specialties have crafted many evidence-based practice guidelines (EBG) that are widely used; these have helped to augment standardization and cost effectiveness. In particular, the use of several "epithelial" and "mesothelial" antibodies has been proposed to distinguish epithelioid malignant mesothelioma from metastatic pulmonary adenocarcinoma. Other authors have previously done systematic literature reviews of this subject up through 2004 and integrated the results of 88 publications into summarized test-performance values for 15 preselected immunohistochemical markers. The results suggested that 7 tests provide optimal sensitivity and specificity (MOC-31, BG8, CEA, TTF-1, CK5/6, WT-1, and HBME-1), but they provide no guidance for integration of such data into EBG. Odds ratios (ORs) were employed to compare the effectiveness of any single test, and chosen combinations thereof, in the differential diagnosis of malignant mesothelioma and metastatic pulmonary adenocarcinoma. Surprisingly, selected single immunostains or antibody pairs yielded ORs (varying from 96.34 to 1233.19) that were equal or better in efficacy when compared with more comprehensive panels. These results support the potential value of systematic reviews, meta-analysis, and OR calculations for development of EBG in diagnostic immunohistology.

12 Guideline Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2007

Anonymous5160584 / Manegold, C. · ·Ann Oncol · Pubmed #17491037.

ABSTRACT: -- No abstract --

13 Guideline Recommendations for the reporting of pleural mesothelioma. 2007

Butnor, Kelly J / Sporn, Thomas A / Ordonez, Nelson G / Anonymous6600594. ·Department of Pathology, University of Vermont, 111 Colchester Avenue, Burlington, VT 05401, USA. kelly.butnor@vtmednet.org · ·Hum Pathol · Pubmed #17276491.

ABSTRACT: It has been evident for decades that pathology reports are very variable even within a single institution. Standardization of reporting is the optimal way to ensure that information necessary for patient management, prognostic and predictive factor assessment, grading, staging, analysis of outcomes, and tumor registries is included in pathology reports. In recent years, 2 societies (first the Association of Directors of Anatomic and Surgical Pathology [ADASP] and then the College of American Pathologists [CAP]) have undertaken to publish guidelines for the reporting of common cancers. The CAP assigned multidisciplinary groups of pathologists, surgeons, radiation, and medical oncologists to develop the protocols. Other pathologists and clinicians then reviewed them. After those reviews the protocols were reviewed by multiple CAP committees and finally approved by the Board of Governors. The ADASP, in contrast, chose a pathologist expert in each filed to assemble a group from within the pathology community (with clinician input if desired) to write specific cancer protocols. These were then approved by the ADASP council and subsequently by the membership. Although both societies began the process at approximately the same time, the streamlined approach adopted by the ADASP enabled them to publish years earlier in pathology journals frequented by anatomic pathologists. Although the formats are somewhat different, the contents are essentially the same. The American College of Surgery Commission on Cancer (COC) accredits cancer centers in the United States. Recently, the COC decided to require elements, deemed as essential by the CAP, to be described in all pathology reports in their accredited cancer centers as of January 2004. Importantly, they do not require that the specific CAP protocols or synoptic reports be used. The ADASP has updated all of its protocols to comply with the COC requirements in the form of 37 uniform checklists. The checklists use the staging criteria sited in the American Joint Committee on Cancer 2002 Staging Manual (sixth edition) but include a variety of other references listed in each of the checklists. Moreover, the checklists are formatted for ease of use. They may be used as templates for uniform reporting and are designed to be compatible with voice-activated transcription. The different elements in these revised ADASP diagnostic checklists have been divided into required and optional. The term required in this context only signifies compliance with the COC guidelines. The ADASP realizes that specimens and practices vary, and it will not be possible to report these elements in every case. However, the ADASP hopes that pathologists will find these checklists to be useful in daily clinical practice, while facilitating compliance with the new COC requirements.

14 Guideline Recommendations for the reporting of pleural mesothelioma. 2007

Anonymous350577. · ·Am J Clin Pathol · Pubmed #17145632.

ABSTRACT: -- No abstract --

15 Guideline Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma. 2007

Scherpereel, Arnaud / Anonymous4000584. ·INSERM Unit 774, Institut Pasteur de Lille, France. a-scherpereel@chru-lille.fr · ·Respir Med · Pubmed #17137779.

ABSTRACT: Previously considered as a rare tumor, malignant pleural mesothelioma (MPM) has become a very important public health issue. In fact, MPM is a tumor with a poor survival, and its incidence is expected to continue to increase for at least the next 10 years. Asbestos exposure is the main factor involved in MPM pathogenesis. The diagnosis of MPM may be difficult because of differential diagnosis such as pleural benign disease induced by asbestos exposure or pleural metastasis of adenocarcinoma. Management of patients with MPM also remains complicated because they are often referred for evaluation late in the evolution of the disease. Moreover, MPM exhibits a high resistance to radiotherapy and chemotherapy; only few patients are candidates for radical surgery. New therapeutic strategies such as gene or cell therapy are still on clinical trial. Therefore, an optimal treatment of MPM is not clearly defined yet, despite the introduction of recent drugs. Between April 2005 and January 2006, the French Speaking Society for Chest Medicine (SPLF), in collaboration with other French scientific societies, brought together experts on mesothelioma to draw up recommendations in order to provide clinicians with clear, concise, up-to-date guidelines on management of MPM, presented in this report.

16 Guideline The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. 2006

Ellis, Peter / Davies, Angela M / Evans, William K / Haynes, Adam E / Lloyd, Nancy S / Anonymous770576. ·McMaster University at Hamilton Health Sciences and Juravinski Cancer Centre, Hamilton, Ontario, Canada. vanderja@mcmaster.ca · ·J Thorac Oncol · Pubmed #17409924.

ABSTRACT: BACKGROUND: This clinical practice guideline, based on a systematic review, was developed to determine which chemotherapeutic agents (or combinations of agents) show the highest response rates, improved survival, quality of life, or symptom control in patients with advanced malignant pleural mesothelioma. METHODS: A thorough systematic search of the literature was conducted for published articles and conference proceedings for applicable abstracts. Relevant trials, published as articles and abstracts, were selected and assessed. External feedback was obtained from Ontario clinicians, and the guideline was approved by the provincial Lung Cancer Disease Site Group. RESULTS: One hundred nineteen studies were eligible, including eight randomized trials and 111 phase II trials. The pooled response rates from phase II trials suggest that response rates with combination chemotherapy are higher than with single agents. Data from the largest randomized controlled trial demonstrated that chemotherapy with cisplatin and pemetrexed significantly improves response rates (41% versus 17%, p < 0.001), time to progression (5.7 months versus 3.9 months, p = 0.001), and overall survival (median, 12.1 months versus 9.3 months, hazard ratio = 0.77, p = 0.020) in comparison to single-agent cisplatin. A second trial demonstrated cisplatin and raltitrexed significantly improved median survival compared to single-agent cisplatin (11.4 months versus 8.8 months; hazard ratio = 0.76, p = 0.0483). Overall response rate (24% versus 14%, p = 0.056) was greater in the combination treatment arm, but this difference was not statistically significant. CONCLUSIONS: There is good evidence to recommend chemotherapy with pemetrexed and cisplatin for adult patients with symptomatic advanced malignant pleural mesothelioma. Such treatment should be administered with supplementation of vitamin B12 and folic acid. If pemetrexed is not available, cisplatin plus raltitrexed is a reasonable alternative.

17 Guideline [Clinical practice guideline on peritoneal carcinomatosis treatment using surgical cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy]. 2006

Kavanagh, Mélanie / Ouellet, Jean-François / Anonymous3950569. ·Direction de la lutte contre le cancer, Ministère de la Santé et des Services sociaux du Québec, 1075, chemin Sainte-Foy, 7e étage, Québec, QC, G1S 2M1, Canada. Melanie.Kavanagh@msss.gouv.qc.ca · ·Bull Cancer · Pubmed #16980229.

ABSTRACT: In 2005, the Comité de l'évolution des pratiques en oncologie (CEPO) took it upon itself to develop a clinical practice guideline to determine the clinical value of surgical cytoreduction followed by hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) for treating peritoneal carcinomatosis stemming from colorectal cancer, cancers of the appendix and stomach, pseudomyxoma peritonei, and mesothelioma of the peritoneum. A review of the scientific literature was performed using the PubMed search engine. The period covered extended from January 1990 to January 2006, inclusively. The scientific literature search was limited to clinical trials (minimum phase II) and organizations elaborating clinical practice recommendations. Twenty-six studies were identified. Of these, only one was phase III. Although some of these studies have demonstrated a benefit from this treatment in terms of patient survival, HIPEC remains a complex procedure whose optimal use is uncertain. Given the morbidity and mortality associated with this treatment, this procedure requires a high level of expertise. Considering the evidence available, the CEPO recommends: 1) that complete cytoreduction followed by HIPEC be used in a clinical research context only, preferably in the presence of an isolated peritoneal carcinomatosis stemming from colorectal cancer, cancer of the appendix, peritoneal pseudomyxoma, or mesothelioma of the peritoneum; 2) that studies be conducted only in specialized centers with the necessary expertise and technical resources.

18 Guideline [The French language Society of Pneumology guidelines on the pleural mesothelioma]. 2006

Anonymous1280565. · ·Rev Mal Respir · Pubmed #16820752.

ABSTRACT: -- No abstract --

19 Editorial 50th Anniversary Perspective on Volume 1: Urschel HC, Paulson DL. Mesotheliomas of the Pleura. Ann Thorac Surg 1965;1:559-73. 2015

Rusch, Valerie W. ·Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: ruschv@mskcc.org. ·Ann Thorac Surg · Pubmed #26434424.

ABSTRACT: -- No abstract --

20 Editorial [III Italian Consensus Conference on pleural mesothelioma]. 2015

Zocchetti, Carlo. ·. carlo.zocchetti@libero.it. ·Med Lav · Pubmed #26384257.

ABSTRACT: -- No abstract --

21 Editorial [The frontage and the other headlines]. 2015

Vignot, Stéphane / Magné, Nicolas. ·Hôpital Louis-Pasteur, service d'oncologie et de hématologie, 6, rue Claude-Bernard, 28630 Chartres Le Coudray, France. Electronic address: svignot@ch-chartres.fr. · Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108 bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez cedex, France. ·Bull Cancer · Pubmed #26281942.

ABSTRACT: -- No abstract --

22 Editorial An update on pleuro-pulmonary cytopathology: Part i: Cytological diagnosis of mesothelioma and molecular cytology of lung cancer with an historical perspective. 2015

Bedrossian, Carlos W M. · ·Diagn Cytopathol · Pubmed #26100968.

ABSTRACT: -- No abstract --

23 Editorial ASIA: asbestos stop in Asia. 2015

Baas, Paul / Burgers, Sjaak. ·Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. · ·Respirology · Pubmed #25828940.

ABSTRACT: -- No abstract --

24 Editorial The mesothelioma enigma. 2015

Flores, Raja M. ·Department of Thoracic Surgery, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: raja.flores@mountsinai.org. ·J Thorac Cardiovasc Surg · Pubmed #25816958.

ABSTRACT: -- No abstract --

25 Editorial Recent insights emerging from malignant mesothelioma genome sequencing. 2015

Carbone, Michele / Gaudino, Giovanni / Yang, Haining. ·University of Hawaii Cancer Center, University of Hawaii, Honolulu, Hawaii. · ·J Thorac Oncol · Pubmed #25695218.

ABSTRACT: -- No abstract --

Next